We’re excited to share that we will be attending the Biosimilar Medicines Conference
This year’s programme focuses on how strategic collaboration across stakeholders and regions can unlock the full potential of biosimilars and drive meaningful impact for patients and healthcare systems.
The agenda will cover key topics such as market competition, access strategies, and regulatory evolution in a rapidly changing global landscape.
Biokinetica’s CEO, Marek Kiecana and COO, Agnieszka Kulesza are looking forward to engaging in these conversations — and beyond industry updates, are ready to discuss upcoming clinical programs and how Biokinetica can support early phase development of your biosimilar study with high-quality delivery, fast enrollment, sharp timelines, and collaborative execution.
If you’re attending the event, let’s get in touch!
